$2500 | Single User
$5000 | Site License
$7500 | Enterprise License

Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016
[Lowest Price Guaranteed: $2,500]

Published by Global Data: 01 Nov 2016 | 27634 | In Stock
Related Topics: Medical , Medical Devices

Introduction

Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, “Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016" provides an overview of Vagus Nerve Stimulators currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vagus Nerve Stimulators pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Vagus Nerve Stimulators under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Vagus Nerve Stimulators and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Vagus Nerve Stimulators under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents
for Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 4

    1.2 List of Figures 6

    2 Introduction 7

    2.1 Vagus Nerve Stimulators Overview 7

    3 Products under Development 8

    3.1 Vagus Nerve Stimulators - Pipeline Products by Stage of Development 8

    3.2 Vagus Nerve Stimulators - Pipeline Products by Territory 9

    3.3 Vagus Nerve Stimulators - Pipeline Products by Regulatory Path 10

    3.4 Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date 11

    3.5 Vagus Nerve Stimulators - Ongoing Clinical Trials 12

    4 Vagus Nerve Stimulators - Pipeline Products under Development by Companies 13

    4.1 Vagus Nerve Stimulators Companies - Pipeline Products by Stage of Development 13

    4.2 Vagus Nerve Stimulators - Pipeline Products by Stage of Development 14

    5 Vagus Nerve Stimulators Companies and Product Overview 15

    5.1 BioControl Medical Company Overview 15

    5.1.1 BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview 15

    5.2 Boston Scientific Corporation Company Overview 17

    5.2.1 Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 17

    5.3 CerboMed GmbH Company Overview 21

    5.3.1 CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview 21

    5.4 Cerebral RX Ltd. Company Overview 22

    5.4.1 Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22

    5.5 Cyberonics, Inc. Company Overview 23

    5.5.1 Cyberonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23

    5.6 DuoCure Ltd. Company Overview 27

    5.6.1 DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview 27

    5.7 ElectroCore, LLC Company Overview 28

    5.7.1 ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview 28

    5.8 LivaNova PLC Company Overview 34

    5.8.1 LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 34

    5.9 Medical University of South Carolina Company Overview 40

    5.9.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 40

    5.10 MicroTransponder Inc. Company Overview 42

    5.10.1 MicroTransponder Inc. Pipeline Products & Ongoing Clinical Trials Overview 42

    5.11 Neurostream Technologies G.P. (Inactive) Company Overview 49

    5.11.1 Neurostream Technologies G.P. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 49

    5.12 Purdue University Company Overview 51

    5.12.1 Purdue University Pipeline Products & Ongoing Clinical Trials Overview 51

    5.13 Setpoint Medical Corp Company Overview 52

    5.13.1 Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 52

    5.14 Trifectas Medical Corp. Company Overview 56

    5.14.1 Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 56

    6 Vagus Nerve Stimulators- Recent Developments 57

    6.1 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 57

    6.2 Oct 19, 2016: SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease 58

    6.3 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results 59

    6.4 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 60

    6.5 Sep 29, 2016: LivaNova Announces Half-Year Financial Report 61

    6.6 Aug 03, 2016: LivaNova Reports Second Quarter 2016 Results 69

    6.7 Aug 01, 2016: LivaNova Names Chief Operating Officer 70

    6.8 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 71

    6.9 Jul 26, 2016: Use of electroCore’s therapy reduces frequency of migraine attacks in chronic patients 72

    6.10 Jul 21, 2016: Reorganization of electroCore management team as Frank Amato becomes CEO and founder JP Errico becomes Chief Science and Strategy Officer 73

    6.11 Jul 20, 2016: St. Jude Medical Reports Second Quarter 2016 Results 73

    6.12 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 75

    6.13 Jul 06, 2016: LivaNova Sets Operating Model and Supporting Organization 75

    6.14 Jul 05, 2016: Breakthrough First-in-Human Study Shows Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis Symptoms, Inhibits Cytokine Production 76

    6.15 Jun 29, 2016: ElectroCore Raises USD1.5 Million in Venture Financing 77

    6.16 Jun 24, 2016: Five presentations at AHS meeting provide new insights into non-invasive vagus nerve stimulation’s mode of action 77

    6.17 Jun 15, 2016: ElectroCore’s non-invasive vagus nerve stimulation (nVNS) demonstrates efficacy in preventing cluster headache and menstrual migraine 78

    6.18 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation 78

    6.19 Jun 06, 2016: Seven presentations on electroCore’s treatment for cluster headache and migraine will feature at American Headache Society science meeting 79

    6.20 May 31, 2016: Ergoresearch announce the nomination of an Executive Vice-President 80

    6.21 May 27, 2016: Ergoresearch Reports its Results for the Quarter Ended March 31, 2016 81

    6.22 May 17, 2016: GammaCore is both effective and cost effective for the treatment of cluster headache 81

    6.23 May 04, 2016: LivaNova Reports First Quarter 2016 Results 82

    6.24 Apr 19, 2016: Studies presented at the American Academy of Neurology meeting confirm nVNS is stimulating the vagus nerve non-invasively and that nVNS can be effective in preventing menstrual migraine 83

    6.25 Apr 01, 2016: NICE provides positive guidance on electroCore’s gammaCore treatment for the prevention and acute treatment of migraine and cluster headache 84

    6.26 Feb 29, 2016: Second Quarter Results ended December 31, 2015 - Ergoresearch reports its results for the quarter ended December 31, 2015 85

    6.27 Feb 24, 2016: LivaNova Reports 2015 Annual and Fourth Quarter Financial Results 85

    6.28 Jan 19, 2016: University of Bonn study shows that non-invasive vagus nerve stimulation (nVNS) device reduces number of migraine attacks and their intensity 88

    6.29 Jan 06, 2016: ElectroCore Appoints Desitin to Launch gammaCore for the Treatment of Primary Headache across Germany 89

    6.30 Jan 05, 2016: LivaNova Provides Update on FDA Warning Letter 89

    6.31 Dec 23, 2015: Mittel Plans to Sell 6% Interest in LivaNova 90

    6.32 Nov 19, 2015: Checkpoint Surgical Raises USD7.5 Million in Venture Financing 90

    6.33 Nov 12, 2015: LivaNova Provides Business Update 90

    7 Appendix 93

    7.1 Methodology 93

    7.2 About GlobalData 95

    7.3 Contact Us 95

    7.4 Disclaimer 96

List Of Tables
in Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016

1.1 List of Tables

Table 1: Vagus Nerve Stimulators - Pipeline Products by Stage of Development 8

Table 2: Vagus Nerve Stimulators - Pipeline Products by Territory 9

Table 3: Vagus Nerve Stimulators - Pipeline Products by Regulatory Path 10

Table 4: Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date 11

Table 5: Vagus Nerve Stimulators - Ongoing Clinical Trials 12

Table 6: Vagus Nerve Stimulators Companies - Pipeline Products by Stage of Development 13

Table 7: Vagus Nerve Stimulators - Pipeline Products by Stage of Development 14

Table 8: BioControl Medical Pipeline Products & Ongoing Clinical Trials Overview 15

Table 9: CardioFit System - Product Status 15

Table 10: CardioFit System - Product Description 16

Table 11: Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 17

Table 12: AMT System - Product Status 17

Table 13: AMT System - Product Description 18

Table 14: Vagal Nerve Stimulator - Product Status 18

Table 15: Vagal Nerve Stimulator - Product Description 18

Table 16: Boston Scientific Corporation - Ongoing Clinical Trials Overview 19

Table 17: Vagal Nerve Stimulator - Neural Cardiac Therapy for Heart Failure Study 20

Table 18: CerboMed GmbH Pipeline Products & Ongoing Clinical Trials Overview 21

Table 19: t-VNS - Dementia - Product Status 21

Table 20: t-VNS - Dementia - Product Description 21

Table 21: Cerebral RX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22

Table 22: FitNes System - Alzheimer’s Disease - Product Status 22

Table 23: FitNes System - Alzheimer’s Disease - Product Description 22

Table 24: Cyberonics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 23

Table 25: Aspire NP - Product Status 23

Table 26: Aspire NP - Product Description 24

Table 27: Centro Generator - Product Status 24

Table 28: Centro Generator - Product Description 24

Table 29: Griffin - Pulse Generator - Product Status 25

Table 30: Griffin - Pulse Generator - Product Description 25

Table 31: Nerve Wrap - Product Status 25

Table 32: Nerve Wrap - Product Description 26

Table 33: PhoenixRF SR - Product Status 26

Table 34: PhoenixRF SR - Product Description 26

Table 35: DuoCure Ltd. Pipeline Products & Ongoing Clinical Trials Overview 27

Table 36: Intraluminal Implantable Device - Product Status 27

Table 37: Intraluminal Implantable Device - Product Description 27

Table 38: ElectroCore, LLC Pipeline Products & Ongoing Clinical Trials Overview 28

Table 39: GammaCore - Cluster Headache - Product Status 28

Table 40: GammaCore - Cluster Headache - Product Description 28

Table 41: GammaCore - Medication Overuse Headache - Product Status 29

Table 42: GammaCore - Medication Overuse Headache - Product Description 29

Table 43: GammaCore - Migraine - Product Status 30

Table 44: GammaCore - Migraine - Product Description 30

Table 45: ElectroCore, LLC - Ongoing Clinical Trials Overview 31

Table 46: GammaCore - Migraine - A Prospective, Multi-center, Randomized, Double-blind, Sham-controlled Study of the gammaCore-S Non-invasive Vagus Nerve Stimulation Device (NVNS), for the Acute Treatment of Migraine 32

Table 47: GammaCore - Cluster Headache - A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of the gammaCore, a Non-invasive Neurostimulator Device, for the Prevention of Episodic Migraine 33

Table 48: GammaCore - Cluster Headache - Non-Invasive Vagus Nerve Stimulation Treatment for Headache Using GammaCore 33

Table 49: LivaNova PLC Pipeline Products & Ongoing Clinical Trials Overview 34

Table 50: CentroSR Generator - Product Status 34

Table 51: CentroSR Generator - Product Description 35

Table 52: Equilia - Product Status 35

Table 53: Equilia - Product Description 35

Table 54: VITARIA System - Chronic Heart Failure - Product Status 36

Table 55: VITARIA System - Chronic Heart Failure - Product Description 36

Table 56: LivaNova PLC - Ongoing Clinical Trials Overview 37

Table 57: VITARIA System - Chronic Heart Failure - VITARIA Registry Study 38

Table 58: Equilia - Vagal Nerve Stimulation: Safe-guarding Heart Failure Patients (VANGUARD) 39

Table 59: Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 40

Table 60: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Status 40

Table 61: Transcutaneous Auricular Vagus Nerve Stimulator (taVNS) - Product Description 41

Table 62: MicroTransponder Inc. Pipeline Products & Ongoing Clinical Trials Overview 42

Table 63: SAINT System - Anxiety Disorders - Product Status 42

Table 64: SAINT System - Anxiety Disorders - Product Description 43

Table 65: SAINT System - Tinnitus - Product Status 43

Table 66: SAINT System - Tinnitus - Product Description 44

Table 67: Serenity System - Tinnitus - Product Status 45

Table 68: Serenity System - Tinnitus - Product Description 45

Table 69: Vivistim Device - Product Status 45

Table 70: Vivistim Device - Product Description 46

Table 71: MicroTransponder Inc. - Ongoing Clinical Trials Overview 47

Table 72: Vivistim Device - A Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function after Stroke (MicroTransponder's Vivistim System) - Study MT-St-02 - Stroke 48

Table 73: Neurostream Technologies G.P. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 49

Table 74: Neuromodulation Device - Epilepsy - Product Status 49

Table 75: Neuromodulation Device - Epilepsy - Product Description 49

Table 76: Neuromodulation Device - Sleep Apnea - Product Status 50

Table 77: Neuromodulation Device - Sleep Apnea - Product Description 50

Table 78: Purdue University Pipeline Products & Ongoing Clinical Trials Overview 51

Table 79: Bionode Device - Product Status 51

Table 80: Bionode Device - Product Description 51

Table 81: Setpoint Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 52

Table 82: Implantable Neurostimulation Device - Rheumatoid Arthritis - Product Status 52

Table 83: Implantable Neurostimulation Device - Rheumatoid Arthritis - Product Description 52

Table 84: SetPoint Immune System Regulator - Crohn’s Disease - Product Status 53

Table 85: SetPoint Immune System Regulator - Crohn’s Disease - Product Description 53

Table 86: Setpoint Medical Corp - Ongoing Clinical Trials Overview 54

Table 87: SetPoint Immune System Regulator - Crohn’s Disease - Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-inflammatory Pathway Using a Vagal Nerve Stimulation Device in Patients with Active Refractory Crohn's Disease 55

Table 88: Trifectas Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 56

Table 89: Neurostimulation Device - Stroke Recovery - Product Status 56

Table 90: Neurostimulation Device - Stroke Recovery - Product Description 56

Table 91: Glossary 94

List Of Figures, Charts and Diagrams
in Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016

1.2 List of Figures

Figure 1: Vagus Nerve Stimulators - Pipeline Products by Stage of Development 8

Figure 2: Vagus Nerve Stimulators - Pipeline Products by Territory 9

Figure 3: Vagus Nerve Stimulators - Pipeline Products by Regulatory Path 10

Figure 4: Vagus Nerve Stimulators - Pipeline Products by Estimated Approval Date 11

Figure 5: Vagus Nerve Stimulators - Ongoing Clinical Trials 12

Additional Details

Publisher

Global Data

Publisher Information

Reference

27634 | GDME0250EPD

Number of Pages

96

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Neuromodulation Devices Market by Technology (Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Spinal Cord Stimulation), Application (Chronic Pain Management, Failed back syndrome, Epilepsy, Tremor, Incontinence, Depression, Dystonia, Gastroparesis, Parkinsons disease, Obsessive-Compulsive Disorder, Migraine) and Biomaterial (Metallic, Polymeric, Ceramic) - Global Opportu
Neuromodulation is the alteration of nerve activity by delivering electrical impulses directly to a ...
09 Aug 2016 by Allied Market Research USD $5,370 More Info
Brain Implants Market: By Type (Deep Brain Stimulator (DBS), Vagus Nerve Stimulator (VNS), and Spinal Cord Stimulator (SCS)), & By Region-Forecast (2016-2021)
Brain implants, also referred as neural implants are connected directly to the brain either by placi...
22 Mar 2016 by USD $5,250 More Info
North America Internal Neuromodulation Market by Type (Spinal Cord, Deep Brain, Sacral Nerve, Vagus Nerve, Gastric Neuro stimulator), Application (Parkinson's Disease, Chronic pain) – Analysis & Forecast to 2019
The North American neuromodulation market is expected to reach ,854.4 million by 2019 at a CAGR of...
13 May 2015 by MicroMarketMonitor USD $2,650 More Info
North America Internal Neuromodulation Market by Type (Spinal Cord, Deep Brain, Sacral Nerve, Vagus Nerve, Gastric Neuro stimulator), Application (Parkinson's Disease, Chronic pain) – Analysis & Forecast to 2019
The North American neuromodulation market is expected to reach ,854.4 million by 2019 at a CAGR of...
13 May 2015 by MarketsandMarkets USD $2,650 More Info
Internal Neurostimulation Market, by Type (Spinal Cord Stimulation, Deep brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation), by Application (Parkinson’s Disease, Chronic Pain), by Geography – Analysis & Forecasts To 2019
Internal neurostimulation involves a surgical implantation of electrodes at specific areas, either i...
07 Apr 2015 by MicroMarketMonitor USD $4,250 More Info
Internal Neurostimulation Market, by Type (Spinal Cord Stimulation, Deep brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation), by Application (Parkinson’s Disease, Chronic Pain), by Geography – Analysis & Forecasts To 2019
Internal neurostimulation involves a surgical implantation of electrodes at specific areas, either i...
07 Apr 2015 by MarketsandMarkets USD $4,250 More Info
Asian Internal Neurostimulaiton/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) -Forecast to 2019
The Asia-Pacific internal neurostimulation/neuromodulation market is estimated to register a CAGR of...
16 Mar 2015 by MicroMarketMonitor USD $2,650 More Info
Asian Internal Neurostimulaiton/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) -Forecast to 2019
The Asia-Pacific internal neurostimulation/neuromodulation market is estimated to register a CAGR of...
16 Mar 2015 by MarketsandMarkets USD $2,650 More Info
Middle East & Africa - Saudi Arabia, South Africa, and Turkey Internal Neurostimulation/Neuromodulation Market [Spinal Cord Stimulation, Vagus Nerve Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Gastric Electric Neurostimulation] - Forecasts till 2019
The internal neuromodulation market in Saudi Arabia, South Africa, and Turkey is a fast emerging mar...
10 Feb 2015 by MicroMarketMonitor USD $2,650 More Info
Middle East & Africa - Saudi Arabia, South Africa, and Turkey Internal Neurostimulation/Neuromodulation Market [Spinal Cord Stimulation, Vagus Nerve Stimulation, Deep Brain Stimulation, Sacral Nerve Stimulation, Vagus Nerve Stimulation, Gastric Electric Neurostimulation] - Forecasts till 2019
The internal neuromodulation market in Saudi Arabia, South Africa, and Turkey is a fast emerging mar...
10 Feb 2015 by MarketsandMarkets USD $2,650 More Info

This report is published by Global Data

Download Free Report Summary PDF

Vagus Nerve Stimulators - Medical Devices Pipeline Assessment, 2016 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...